Houston Methodist Division of Medical Oncology & Malignant Hematology 

In the Houston Methodist Division of Medical Oncology & Malignant Hematology, our medical oncologists are exceptional clinicians, researchers and educators. Treating around 7,000 new cancer cases each year, we are committed to providing the highest level of care to each patient, while educating the next generation of oncologists. 

The Texas Medical Center functions as a centralized research hub, with deeply interconnected locations across the region. Our seven community hospitals are all equipped to offer similar care in collaboration with disease-specific experts and extend and amplify the division’s expertise. 

Our multidisciplinary team collaborates across the system and externally. Our nationally known physicians present abstracts and publications at conferences around the world.  

Our division ethos is centered in evidence-based research, pioneering treatment to all, with a focus on patient care. We understand the complex connections between personalized treatment, clinical care outcomes and innovation. We train our physicians, nutritionists, social workers, counselors and nurse navigators to work together to adopt a values driven framework of empathy and collaboration in the delivery of care. 

 

Our Faculty ➝   Our Physicians ➝ 

The Houston Methodist Division of Medical Oncology & Malignant Hematology includes a robust team of physician-scientists conducting basic translational research and clinical trials at all phases. Many of our trials are investigator-initiated, developed and repurposed in our laboratories. Our active members within the Neal Cancer Center conduct research, publish peer reviewed papers, and hold grants from governmental and non-governmental sources — totaling nearly $17 million in annual direct research funding. 

Many of our members are active in national committees, establishing guidelines and policies related to cancer treatment and research. Houston Methodist Neal Cancer Center physicians and scientists are visible and sought after in both national and international research arenas. Our division regularly produces peer-reviewed publications in high impact journals and with multi-institutional collaboration. 

Our groundbreaking research includes ER stress physiology, molecular resistance in patients with CLL, newer modalities of therapy repurposing ATRA in the management of relapsed refractory myeloma, and work to understand how obesity influences myeloma development and developing novel immunotherapy, especially CAR-T in hematological malignancies.  

A recent endeavor includes our work to produce our very own cellular CAR-T product, and we collaborate with the divisions of neurology, rheumatology, surgery and orthopedics on cell therapy studies. 

Our Ann Kimball & John W. Johnson Center for Cellular Therapeutics is accredited by the international FACT organization. Since its inception, the Johnson Center has been involved with many cellular therapy trials both for the Neal Cancer Center as well as with other divisions within the Department of Medicine. For example, we worked closely with the Cockrell Center for Advanced Therapeutics Phase I program and helped to open CAR-T clinical trials for neurological and autoimmune diseases. 

We are passionate in our efforts to discover new therapies that extend survival, and that improve or lessen treatment side effects. Division members publish their work in high-impact, multi-institutional journals and are visible in various national and international meetings, including American Society of Hematology, Tandem BMT Meetings, European Hematology Association Congress, American Association for Cancer Research and American Association of Oncology. 

Physicians throughout our division invest their time and knowledge into the education of the next generation of oncology and hematology leaders. We mentor medical students at multiple levels, from undergraduate research fellows to post-PhD graduate fellows and community health workers. 

Our ACGME-accredited Hematology-Oncology Fellowship is a three-year program equipping fellows with a diverse range of knowledge and competencies, including cancer prevention, clinical cancer genetics, health policy and cost-effective evidence-based patient care, along with translational and clinical research experience. Fellows perform rotations at Legacy Community Health, providing care for underserved patient populations. 

We offer grand rounds, tumor boards and didactic conferences, including a resident-led morning report, board review, journal club, morbidity and mortality system-based practice, quality improvement/patient safety training, and more. 

Texas A&M University medical students perform clinical training and in-patient rotations with us through the EnMed program. We help organize a statewide lymphoma conference with several cancer centers across Texas. Regular journal club meetings are held with the myeloma team at MD Anderson Cancer Center. We also engage in efforts to educate the community about cancer prevention and care. We help organize a statewide lymphoma conference with several cancer centers across Texas. We also engage in efforts to educate the community about cancer prevention and care.